Earnings NewsHealthcareINmune Bio GAAP EPS of -$1.88 misses by $1.30, revenue of $0.18MMar. 03, 2022 4:03 PM ETINmune Bio, Inc. (INMB)By: Urvi Shah, SA News Editor INmune Bio press release (NASDAQ:INMB): Q4 GAAP EPS of -$1.88 misses by $1.30. Revenue of $0.18M (+63.6% Y/Y). Recommended For YouCommentsNewestPublishHave a tip? Submit confidentially to our News team. Found a factual error? Report here.More Trending NewsCatalyst Watch: McDonald's event, Lululemon earnings and GameStop volatility reduxBitcoin rally bodes well for miners’ profit prospectsCharles Schwab files for mixed shelfPlug Power surges to top industrial gainer of week, Kanzhun sees No. 1 loser tagRTX awarded $145M army contractSee More »About INMBSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapPEYield (TTM)Rev Growth (YoY)Short InterestPrev. CloseCompare to PeersRelated StocksSymbolLast Price% ChgINMB--INmune Bio, Inc.XOMA--XOMA CorporationALT--Altimmune, Inc.STOK--Stoke Therapeutics, Inc.ATXS--Astria Therapeutics, Inc.CompareTrending AnalysisTrending News